Clearside Biomedical, Inc. Quarterly Debt-to-equity in % from Q1 2017 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Clearside Biomedical, Inc. quarterly Debt-to-equity history and growth rate from Q1 2017 to Q3 2024.
  • Clearside Biomedical, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -236 %, a 93.9% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -236 +3.62K +93.9% Sep 30, 2024
Q2 2024 -281 -891 -146% Jun 30, 2024
Q1 2024 -366 -586 -267% Mar 31, 2024
Q4 2023 -591 -693 -680% Dec 31, 2023
Q3 2023 -3.86K -3.9K -8528% Sep 30, 2023
Q2 2023 610 +589 +2730% Jun 30, 2023
Q1 2023 219 +193 +736% Mar 31, 2023
Q4 2022 102 +64.4 +172% Dec 31, 2022
Q3 2022 45.8 -18.1 -28.3% Sep 30, 2022
Q2 2022 21.6 -53.5 -71.3% Jun 30, 2022
Q1 2022 26.3 -73.7 -73.7% Mar 31, 2022
Q4 2021 37.5 -92.2 -71.1% Dec 31, 2021
Q3 2021 63.8 -71.1 -52.7% Sep 30, 2021
Q2 2021 75 -71.9 -48.9% Jun 30, 2021
Q1 2021 99.9 -43.1 -30.1% Mar 31, 2021
Q4 2020 130 -10.8 -7.69% Dec 31, 2020
Q3 2020 135 +14.7 +12.2% Sep 30, 2020
Q2 2020 147 +59.9 +68.7% Jun 30, 2020
Q1 2020 143 +84.1 +143% Mar 31, 2020
Q4 2019 141 +102 +261% Dec 31, 2019
Q3 2019 120 +81.6 +211% Sep 30, 2019
Q2 2019 87.1 +50.6 +139% Jun 30, 2019
Q1 2019 58.9 +23.8 +67.8% Mar 31, 2019
Q4 2018 38.9 +2.22 +6.05% Dec 31, 2018
Q3 2018 38.6 +12.5 +48.1% Sep 30, 2018
Q2 2018 36.5 +14.5 +65.7% Jun 30, 2018
Q1 2018 35.1 +13.9 +65.7% Mar 31, 2018
Q4 2017 36.7 Dec 31, 2017
Q3 2017 26.1 Sep 30, 2017
Q2 2017 22 Jun 30, 2017
Q1 2017 21.2 Mar 31, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.